Core Viewpoint - The company, Hangzhou Aotai Biotechnology Co., Ltd., is utilizing temporarily idle raised funds for cash management to enhance fund efficiency and returns for shareholders while ensuring that it does not affect the progress of investment projects [1][8]. Fundraising Overview - The company raised a total of RMB 1,804,545,000 through its initial public offering, with a net amount of RMB 1,643,266,906.25 after deducting issuance costs [1]. - The funds are stored in a special account approved by the board of directors, and a tripartite supervision agreement has been signed with the sponsor and the commercial bank [1]. Investment Projects - The raised funds are planned to be invested in projects including the construction of a production and R&D center for in vitro diagnostic reagents, with a total investment of RMB 146,059,100 [2][3]. Cash Management Details - The company plans to use up to RMB 480 million of temporarily idle funds for cash management, investing in low-risk, highly liquid products with a maturity of no more than 12 months [5][6]. - The cash management products include but are not limited to agreement deposits, structured deposits, and large certificates of deposit [5]. Approval Process - The board of directors and the supervisory board have approved the cash management plan, which does not require shareholder approval [7][8]. - The company will ensure compliance with relevant regulations and maintain transparency in information disclosure [5][8]. Impact on Operations - The cash management strategy is designed to improve fund efficiency without impacting the company's daily operations or the progress of investment projects [6][8].

Core Viewpoint - The company, Zhejiang Oriental Gene Biotech Co., Ltd., reported a slight increase in revenue for 2024, but a significant loss in net profit, primarily due to a decline in domestic sales and a contrasting increase in international sales [1][2]. Revenue Analysis - The company's total revenue for 2024 was 828 million yuan, a year-on-year increase of 0.95%, while the net profit attributable to shareholders was -529 million yuan, a year-on-year increase in loss of 33.06% [1]. - Domestic revenue was 207 million yuan, a decline of 35.7%, while international revenue reached 605 million yuan, an increase of 23.14% [1][2]. - The overall product sales volume decreased by 16.1% in 2024 [1]. Product Sales Breakdown - Domestic sales were primarily from the infectious disease testing series, which accounted for 39.52% of domestic revenue, but saw a volume decrease of 21.70% [1]. - The COVID-19 testing series generated 55.33% of domestic revenue but experienced a significant volume decline of 75.37% [1]. - Internationally, the drug testing series accounted for 49.67% of revenue, with a slight increase in sales volume [1][2]. Customer Analysis - The top domestic customers included new clients from trade and existing clients in infectious disease testing, with significant fluctuations in sales due to the COVID-19 product line [2]. - Internationally, major clients included large chain pharmacies in the U.S. and new clients in Mexico, contributing to the overall revenue growth [2][3]. Cost and Profit Margin - The company's operating costs for 2024 were 554 million yuan, an increase of 21.26%, with direct materials and manufacturing costs rising by 15.91% and 54.36%, respectively [5]. - The gross profit margins for domestic and international sales were 54.26% and 24.07%, respectively, both showing a decline compared to the previous year [5][6]. Market Dynamics - The decline in domestic sales was attributed to a significant drop in COVID-19 product sales, while international sales benefited from acquisitions and new product launches [3][5]. - The company expanded its market presence in Africa and introduced new online sales models, contributing to the increase in international revenue [3][4].

Core Viewpoint - Shenzhen Pumen Technology Co., Ltd. has successfully acquired the land use rights for a state-owned construction site in Anhui Province for the "In Vitro Diagnostic Reagent Industrialization Project" at a cost of 3.23 million RMB [1][3]. Group 1: Project Overview - The company approved the investment project on June 24, 2024, and signed an investment agreement with the Anhui He County Economic Development Zone Management Committee [2]. - The project involves establishing a wholly-owned subsidiary, Anhui Puhe Biotechnology Co., Ltd., to operate the investment project [2][3]. - The total area of the project site is 21,516.17 square meters (approximately 32.27 acres), with a required investment intensity of at least 2.4 million RMB per acre [3]. Group 2: Land Acquisition Details - On May 21, 2025, Anhui Puhe signed a confirmation letter with the He County Natural Resources and Planning Bureau regarding the acquisition of the land use rights for the designated plot [3][4]. - The acquisition does not constitute a related party transaction or a significant asset restructuring as defined by the relevant regulations [3][4]. Group 3: Impact on the Company - The land will be utilized for the "In Vitro Diagnostic Reagent Industrialization Project," enhancing the company's R&D and manufacturing capabilities in the East China region [4]. - The project is expected to improve product supply capacity, order response speed, and reduce logistics costs, thereby enhancing profitability and promoting sustainable development [4]. Group 4: Funding and Financial Impact - The funding for the land acquisition and project construction will come from self-owned or self-raised funds, which will not affect the normal operations of the company [4]. - The project is not anticipated to have a significant impact on the company's financial or operational status [4].

Core Viewpoint - The company reported a decline in net profit for the first quarter of 2025, primarily due to changes in the VAT calculation method for in vitro diagnostic reagents, leading to a decrease in operating revenue compared to the same period last year [4][5][6]. Financial Data Summary - The first quarter financial report is unaudited [3]. - The company's net profit decreased compared to the same period last year, attributed to the adjustment of the VAT calculation method for in vitro diagnostic reagents, resulting in a decline in operating revenue [4]. - The net cash flow from operating activities decreased by 134.97% compared to the same period last year, mainly due to reduced accounts receivable collections from the subsidiary [4]. Shareholder Information - As of the end of the reporting period, the company held 1,291,428 shares in its repurchase account, accounting for 3.23% of the total share capital [6]. Board Meeting Resolutions - The company held its 11th meeting of the second board on April 28, 2025, where several resolutions were passed, including the approval of the 2024 annual general manager's work report and the 2024 annual board work report [9][11]. - The board also approved the 2024 financial settlement report and the 2024 annual report, which will be submitted for shareholder approval [13][16]. Profit Distribution Plan - The company proposed a cash dividend of 1.00 yuan per 10 shares (including tax), with a total distribution amounting to 3,870,857.20 yuan based on the adjusted total shares [99][100]. - The profit distribution plan is subject to approval at the 2024 annual general meeting [101][103]. Related Transactions - The company plans to use idle funds to purchase financial products from Jiangnan Rural Commercial Bank, with a maximum balance of 50 million yuan and a term not exceeding 12 months [63][64]. - This transaction has been approved by the board and will be submitted for shareholder approval [79][80]. Audit Firm Appointment - The company intends to reappoint Lixin Certified Public Accountants as its auditor for the 2025 fiscal year, pending shareholder approval [86][87]. - Lixin has a strong track record and has provided audit services to numerous listed companies [88][89].

Core Viewpoint - The report outlines the continuous supervision and tracking of Jiangsu Haooubo Biopharmaceutical Co., Ltd. by Huatai United Securities, highlighting the company's financial performance, risks, and core competitiveness in the in vitro diagnostic reagent industry. Group 1: Risk Factors - The company faces risks related to new product development and registration, as the in vitro diagnostic reagent industry requires significant time and investment for product approval [1][2]. - There is a risk of core technology leakage and loss of key personnel, which could lead to economic losses for the company [2]. - The company may encounter challenges in expanding new business lines, particularly with the Oduoke series products, which are currently limited to specific regions and require effective marketing efforts [2][3]. - The enzyme-linked immunosorbent assay (ELISA) products may be at risk of being replaced by chemiluminescence products due to the latter's technological advantages [3]. - The food-specific IgG testing products face scrutiny regarding their clinical significance, which could impact sales if regulatory bodies withdraw approval [4]. Group 2: Financial Performance - For the year 2024, the company's operating income was approximately 402.34 million yuan, reflecting a 2.01% increase compared to 2023 [9]. - The net profit attributable to shareholders decreased by 22.24% to approximately 36.80 million yuan, primarily due to increased clinical expenses for the Oduoke product and higher stock incentive costs [10]. - The company's total assets increased by 8.80% to approximately 1.03 billion yuan, while the net assets attributable to shareholders rose by 0.17% [9]. Group 3: Core Competitiveness - The company aims to solidify its market share in the allergy testing field and expand its presence in the autoimmune testing sector through advanced chemiluminescence technology [11]. - With over 300 million allergy patients in China, the allergy testing market presents significant growth potential, and the company has established a comprehensive product menu and scale advantages [11][12]. - The company has developed a nationwide sales and service network, with approximately 700 distributors, enhancing its market reach and brand influence [12]. - Continuous investment in research and development is evident, with R&D expenses amounting to approximately 46.27 million yuan, representing 11.50% of operating income [13].

Group 1 - The core viewpoint of the report is to summarize the sponsorship and regulatory compliance of Jiangsu Haobio Pharmaceutical Co., Ltd. during its initial public offering (IPO) on the Sci-Tech Innovation Board [1] - The issuer, Jiangsu Haobio Pharmaceutical Co., Ltd., has a registered capital of 63.058328 million yuan and was listed on January 13, 2021 [1] - The sponsor, Huatai United Securities Co., Ltd., conducted due diligence and prepared application documents in accordance with relevant laws and regulations [1][3] Group 2 - During the continuous supervision period, the sponsor conducted on-site inspections to check the use of raised funds, project progress, and corporate governance [3][4] - The sponsor identified non-operating fund occupation by related parties and conducted a special on-site inspection, requiring the company to strengthen internal training and governance [3][10] - The sponsor issued 26 verification opinions on the issuer's use of raised funds and related transactions, with no disapproval opinions issued [6][13] Group 3 - The issuer established a special account for raised funds and signed a tripartite supervision agreement with the sponsor and relevant banks [4] - The issuer's actual controller was involved in non-operating fund occupation, leading to internal penalties and a requirement to return the occupied funds [8][11] - The issuer's compliance with information disclosure requirements was affirmed, with no undisclosed matters identified [12][13] Group 4 - The report indicates that the issuer strictly followed regulations regarding the use of raised funds and fulfilled information disclosure obligations accurately [13] - The sponsor will continue to oversee the use of funds for the "New In Vitro Diagnostic Reagent R&D Center Project" until all funds are utilized [13]

Group 1: Company Guarantees - The company provides guarantees for its wholly-owned subsidiaries to enhance overall financing efficiency, aligning with operational needs [1][2] - The total amount of guarantees provided to subsidiaries is RMB 200 million, accounting for 24.63% of the latest audited net assets and 19.36% of total assets [2] Group 2: Fundraising and Usage - The company raised a total of RMB 555.86 million through its initial public offering, with a net amount of RMB 496.47 million after deducting related expenses [5][6] - As of December 31, 2024, the company has strictly adhered to its fundraising management policies, ensuring funds are stored in dedicated accounts and used appropriately [7][8] Group 3: Fund Management and Investment - The company has not used idle fundraising for temporary working capital or to repay bank loans as of December 31, 2024 [9][11] - The company has approved the use of up to RMB 200 million of temporarily idle funds for cash management, ensuring safety and liquidity [9][10] Group 4: Project Updates - The company has decided to conclude certain fundraising projects and extend the timeline for others, specifically the "New In Vitro Diagnostic Reagent R&D Center Project" to September 2025 [12][13] - There are no changes in the use of funds for fundraising projects as of December 31, 2024 [14] Group 5: Compliance and Verification - The company has received positive verification from its accounting firm regarding the management and usage of fundraising, confirming compliance with relevant regulations [16][17]